RCEL
RCEL
NASDAQ · Biotechnology

Avita Medical Inc

$16.59
+0.91 (+5.80%)
As of Nov 14, 2:24 AM ET ·
Financial Highlights (FY 2026)
Revenue
78.86M
Net Income
-53,505,623
Gross Margin
83.3%
Profit Margin
-67.9%
Rev Growth
+27.7%
D/E Ratio
9.39
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 83.3% 83.3% 48.8% 48.8%
Operating Margin -59.4% -53.5% -12.4% -14.4%
Profit Margin -67.9% -64.5% -9.8% -12.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 78.86M 61.77M 25.19M 23.71M
Gross Profit 65.66M 51.43M 12.30M 11.58M
Operating Income -46,843,368 -33,024,464 -3,131,948 -3,413,299
Net Income -53,505,623 -37,721,338 -2,467,246 -2,847,172
Gross Margin 83.3% 83.3% 48.8% 48.8%
Operating Margin -59.4% -53.5% -12.4% -14.4%
Profit Margin -67.9% -64.5% -9.8% -12.0%
Rev Growth +27.7% +27.7% +20.8% +14.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 230.01M 230.01M 29.07M 27.04M
Total Equity 24.50M 24.50M 72.39M 66.00M
D/E Ratio 9.39 9.39 0.40 0.41
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -44,255,124 -32,933,078 -4,050,890 -3,804,791
Free Cash Flow — — -1,532,934 -2,480,233